Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition
Open access

Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217

Lydia Trudel J. Therriault Arthur C. Macedo É. Aumont S. A. Hosseini A. Benedet L. Hazrati S. Gauthier H. Zetterberg P. Vitali N. Ashton P. Rosa-Neto
Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 33 references
Medicine

TL;DR

Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited.

Abstract

Staging amyloid beta (Aβ) burden along a continuous spectrum provides clinically relevant information. Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited. Recently developed brain‐derived (BD) p‐tau217 assays enrich for central nervous system tau species and may improve specificity.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Aug 2026

Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer’s disease

Blood-based biomarkers could broaden access to Alzheimer’s disease diagnostics, but their ability to approximate tau PET, and to address gray-zone results, remains uncertain. We evaluated plasma p-tau217 against tau PET using a harmonized ADNI baseline cohort and an independently derived temporal meta-ROI tau-PET thres...

Yasaman Abtahi, Nikki Ghadiminia, Hamide Nasiri et al. · 0 citations
Open access Aug 2026

Plasma p-Tau217 and SPECT-Based eZIS in Mild Cognitive Impairment: Concordance Analysis with Validation in an Amyloid PET Sub-Cohort

Plasma p-Tau217 showed a stronger association with cerebral amyloid pathology than eZIS indices in this elderly MCI cohort, and eZIS may provide complementary information regarding downstream neurodegenerative and cerebrovascular processes that are not directly captured by plasma biomarkers.

I-Lun Huang, Hiroshi Matsuda, Ya-Tang Pai et al. · 0 citations
Review Open access Sep 2026

CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS–FTD Spectrum: A Systematic Narrative Review and Evidence Map

Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology...

Aasim Ali, Muhammad Arif, Usama Ashraf et al. · 0 citations
Sep 2026

Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.

Lower Aβ42 was associated with subsequent ARIA, but the internally derived cutoff requires external validation, and the internally derived cutoff requires external validation.

R. Takahashi, Tetsuo Kashibayashi, Jun Fujita et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.